— Published Date: 12/21/24
Value proposition: A cost-effective, drug-based therapy targeting the endothelin B receptor (ETBR) to promote peripheral nerve regeneration, offering improved recovery and compatibility with existing treatments.
Technology Description
Researchers at Washington University…
— Published Date: 5/14/2025
Value proposition: Novel ASOs that increase key protein production to limit neurodegeneration caused by ALS and frontotemporal dementia (FTD).
Technology Description
TDP-43 pathology is present in ~97% of ALS, ~50% of FTD, and frequently observed in other neurodegenerat…
— Published date: 1/9/2025
Value Proposition: Genetically engineered yeast used to treat gastrointestinal tumors through the delivery of immune checkpoint inhibitor (ICI) proteins.
Technology Description
Researchers at Washington University in St. Louis have developed a genetically engineered …
— Published Date: 12/19/2024
Value Proposition: New method for expanding T cells against individualized tumor-specific mutational antigens.
Technology Description
Researchers at Washington University in St. Louis have developed a device that enables high-throughput production of patient specific …
— Value Proposition: Small molecule Gastrin-releasing peptide receptor (GRPR) antagonists used to treat chronic itch.
Technology Description
Researchers at Washington University in St. Louis have discovered a group of small molecule Gastrin-releasing peptide receptor (GRPR) antagonists to treat c…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
